bioAffinity Technologies
BIAF
5 hedge funds and large institutions have $177K invested in bioAffinity Technologies in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.09% less ownership
Funds ownership: 1.22% → 1.13% (-0.09%)
9% less capital invested
Capital invested by funds: $193K → $177K (-$16.5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.48K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$8.28K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.14K |
BIAF Hedge Fund Activity: Q2 2023 in Review
5 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in bioAffinity Technologies (BIAF) for Q2 2023, worth a combined $177K — down 8.5% from $193K a quarter earlier.
Fund positioning in BIAF was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $2.48K. The largest seller was Two Sigma Investments, cutting an estimated $8.28K.
- 5 institutional investors held bioAffinity Technologies (BIAF) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $177K of bioAffinity Technologies stock for Q2 2023, down 8.5% quarter-over-quarter.
- 1 fund opened new bioAffinity Technologies positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest bioAffinity Technologies buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $2.48K added.
- The largest bioAffinity Technologies seller in Q2 2023 was Two Sigma Investments, an estimated $8.28K sold.
Based on aggregated 13F filings for Q2 2023.